Back to 
Farallon Capital Management, L.L.C.
Farallon Capital Management, L.L.C.
SYRE
Showing 1 of 3 quarters
Position history for Farallon Capital Management, L.L.C.'s holdings in Spyre Therapeutics, Inc.
No. Farallon Capital Management exited its SYRE (Spyre Therapeutics) position in Q3 2024. Its Q2 2024 13F listed 666,000 shares worth $15.7M. Farallon Capital Management first reported SYRE in Q1 2024 and held it in 2 quarterly 13F filings.
Final Value
$0
Final Shares
0
Total Value Change
$0
Total Shares Change
0
Quarter-by-Quarter History